GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into an agreement with Abbott to seek additional development paths for multiple Abbott drug candidates. All of these drug candidates have successfully passed Phase I human clinical trials.
